Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
Journal of Endocrinology · 23.01.2023 · 257 (1)
DOI: 10.1530/joe-22-0155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, erschienen am 23.01.2023. Verfasst von Samuel M Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Non-alcoholic Fatty Liver Disease, Thiazolidinediones. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Peroxisome proliferator-activated receptor γ (PPARγ) belongs to a family of nuclear receptors that could serve as lipid sensors. PPARγ is the target of a group of insulin sensitizers called thiazolidinediones (TZDs) which regulate the expression of genes involved in glucose and lipid metabolism as well as adipokines that regulate metabolic function in other tissues. Non-alcoholic fatty liver disease (NAFLD) has a high prevalence worldwide and is even higher in patients with obesity and insulin resistance. TZD-mediated activation of PPARγ could serve as a good treatment for NAFLD because TZDs have shown anti-fibrogenic and anti-inflammatory effects in vitro and increase insulin sensitivity in peripheral tissues which improves liver pathology. However, mechanistic studies in mouse models suggest that the activation of PPARγ in hepatocytes might reduce or limit the therapeutic potential of TZD against NAFLD. In this review, we briefly describe the short history of PPAR isoforms, the relevance of their expression in different tissues, as well as the pathogenesis and potential therapeutics for NAFLD. We also discuss some evidence derived from mouse models that could be useful for endocrinologists to assess tissue-specific roles of PPARs, complement reverse endocrinology approaches, and understand the direct role that PPARγ has in hepatocytes and non-parenchymal cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA.
ORCID-Profile: Jose Cordoba-Chacon
Förderung
- NIDDK NIH HHS
Zitieren
APA
Lee, S. M., Muratalla, J., Sierra-Cruz, M., & Cordoba-Chacon, J. (2023). Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Journal of Endocrinology, 257(1). https://doi.org/10.1530/joe-22-0155
Vancouver
Lee SM, Muratalla J, Sierra-Cruz M, Cordoba-Chacon J. Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Journal of Endocrinology. 2023;257(1). doi:10.1530/joe-22-0155
BibTeX
@article{Lee2023,
author = {Lee, Samuel M and Muratalla, Jose and Sierra-Cruz, Marta and Cordoba-Chacon, Jose},
title = {Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease},
journal = {Journal of Endocrinology},
year = {2023},
volume = {257},
number = {1},
doi = {10.1530/joe-22-0155}
}
EUVIMED